Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2011

01-03-2011

Tumor immune surveillance and ovarian cancer

Lessons on immune mediated tumor rejection or tolerance

Authors: Lana E. Kandalaft, Gregory T. Motz, Jaikumar Duraiswamy, George Coukos

Published in: Cancer and Metastasis Reviews | Issue 1/2011

Login to get access

Abstract

In the past few years, cancer immunotherapies have produced promising results. Although traditionally considered unresponsive to immune therapy, increasing evidence indicates that ovarian cancers are, in fact, immunogenic tumors. This evidence comes from diverse epidemiologic and clinical data comprising evidence of spontaneous antitumor immune response and its association with longer survival in a proportion of ovarian cancer patients; evidence of tumor immune evasion mechanisms and their association with short survival in some ovarian cancer patients; and finally pilot data supporting the efficacy of immune therapy. Below we will discuss lessons learned on the biology underlying ovarian cancer immune rejection or tolerance and we will discuss its association with clinical outcome. We will discuss the role of angiogenesis and the tumor endothelium on regulation of the antitumor immune response with a special emphasis on the role of vascular endothelial growth factor (VEGF) in the suppression of immunological processes, which control tumor progression and its unique crosstalk with endothelin systems, and how their interactions may shape the antitumor immune response. In addition, we will discuss mechanisms of tumor tolerance through the suppression or exhaustion of effector cells and how these could be countered in the clinic. We believe that understanding these pathways in the tumor microenvironment will lead to novel strategies for enhancing ovarian cancer immunotherapy.
Literature
1.
Bukowski, R. M., Ozols, R. F., & Markman, M. (2007). The management of recurrent ovarian cancer. Seminars in Oncology, 34(2 Suppl 2), S1–S15.PubMed
2.
Ozols, R. F. (2006). Systemic therapy for ovarian cancer: current status and new treatments. Seminars in Oncology, 33(2 Suppl 6), S3–S11.PubMed
3.
Gajewski, T. F. (2006). Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clinical Cancer Research, 12(7 Pt 2), 2326s–2330s.PubMed
4.
Gajewski, T. F., et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunological Reviews, 213, 131–145.PubMed
5.
Yigit, R., et al. (2010). Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecologic Oncology, 117(2), 366–372.PubMed
6.
Nagaraj, S., & Gabrilovich, D. I. (2008). Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Research, 68(8), 2561–2563.PubMed
7.
Hamanishi, J., et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360–3365.PubMed
8.
Schlienger, K., et al. (2003). TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical Cancer Research, 9(4), 1517–1527.PubMed
9.
Zhang, L., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348(3), 203–213.PubMed
10.
Adams, S. F., et al. (2009). Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer, 115(13), 2891–2902.PubMed
11.
Clarke, B., et al. (2008). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss. Modern Pathology (in press)
12.
Sato, E., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18538–18543.PubMed
13.
Shah, C. A., et al. (2008). Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol.
14.
Tomsova, M., et al. (2008). Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecologic Oncology, 108(2), 415–420.PubMed
15.
Stumpf, M., et al. (2009). Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. British Journal of Cancer, 101(9), 1513–1521.PubMed
16.
Milne, K., et al. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE, 4(7), e6412.PubMed
17.
Albert, M. L., et al. (1998). Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Natural Medicines, 4(11), 1321–1324.
18.
Chiriva-Internati, M., et al. (2010). Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS ONE, 5(5), e10471.PubMed
19.
Coukos, G., et al. (2005). Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 5(9), 1193–1210.PubMed
20.
Gordan, J. D., & Vonderheide, R. H. (2002). Universal tumor antigens as targets for immunotherapy. Cytotherapy, 4(4), 317–327.PubMed
21.
Vonderheide, R. H., et al. (1999). The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10(6), 673–679.PubMed
22.
Counter, C. M., et al. (1994). Telomerase activity in human ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 91(8), 2900–2904.PubMed
23.
Freedman, R. S., & Platsoucas, C. D. (1996). Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treatment and Research, 82, 115–146.PubMed
24.
Pertl, U., et al. (2001). IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. Journal of Immunology, 166(11), 6944–6951.
25.
Nehme, A., et al. (1994). Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. European Journal of Cancer, 30A(4), 520–525.PubMed
26.
Melichar, B., et al. (2003). rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. Journal of Translational Medicine, 1(1), 5.PubMed
27.
Wall, L., et al. (2003). The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecologic Oncology, 88(1 Pt 2), S149–S151.PubMed
28.
Freedman, R. S., et al. (2000). Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clinical Cancer Research, 6(6), 2268–2278.PubMed
29.
Kooi, S., et al. (1996). HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cellular Immunology, 174(2), 116–128.PubMed
30.
Coughlin, C. M., et al. (1998). Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9(1), 25–34.PubMed
31.
Maheshwari, R. K., et al. (1991). Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. Journal of Cellular Physiology, 146(1), 164–169.PubMed
32.
Sidky, Y. A., & Borden, E. C. (1987). Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Research, 47(19), 5155–5161.PubMed
33.
Sgadari, C., et al. (1997). Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood, 89(8), 2635–2643.PubMed
34.
Strieter, R. M., et al. (1995). The role of CXC chemokines as regulators of angiogenesis. Shock, 4(3), 155–160.PubMed
35.
Stewart, R. J., Kashour, T. S., & Marsden, P. A. (1996). Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells. Journal of Immunology, 156(3), 1221–1228.
36.
Ruegg, C., Dormond, O., & Foletti, A. (2002). Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium, 9(3), 151–160.PubMed
37.
Qin, Z., et al. (2003). A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Research, 63(14), 4095–4100.PubMed
38.
Edwards, R. P., et al. (1997). Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. Journal of Clinical Oncology, 15(11), 3399–3407.PubMed
39.
Vlad, A.M., et al., A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother, 2009.
40.
Hodi, F. S., et al. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3005–3010.PubMed
41.
Hodi, F. S., et al. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4712–4717.PubMed
42.
Pujade-Lauraine, E., et al. (1996). Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. Journal of Clinical Oncology, 14(2), 343–350.PubMed
43.
Chen, J. T., Hasumi, K., & Masubuchi, K. (1992). Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer–a preliminary trial. Biotherapy, 5(4), 275–280.PubMed
44.
Colombo, N., et al. (1992). Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. International Journal of Cancer, 51(1), 42–46.
45.
Schmeler, K. M., et al. (2009). A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecologic Oncology, 113(2), 210–215.PubMed
46.
Berek, J. S. (2000). Interferon plus chemotherapy for primary treatment of ovarian cancer. Lancet, 356(9223), 6–7.PubMed
47.
Windbichler, G. H., et al. (2000). Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. British Journal of Cancer, 82(6), 1138–1144.PubMed
48.
Alberts, D. S., et al. (2008). Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology, 109(2), 174–181.PubMed
49.
Odunsi, K., et al. (2007). Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(31), 12837–12842.PubMed
50.
Oei, A. L., et al. (2008). The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). International Journal of Oncology, 32(6), 1145–1157.PubMed
51.
Wolf, D., et al. (2005). The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clinical Cancer Research, 11(23), 8326–8331.PubMed
52.
Curiel, T. J., et al. (2004). Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Research, 64(16), 5535–5538.PubMed
53.
Oei, A. L., et al. (2007). Induction of IgG antibodies to MUC1 improves survival in patients with epithelial ovarian cancer. Gynecologic Oncology, 104(3), S11–S11.
54.
Oei, A. L. M., et al. (2008). Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. International Journal of Cancer, 123(8), 1848–1853.
55.
Takikawa, O. (2005). Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism. Biochemical and Biophysical Research Communications, 338(1), 12–19.PubMed
56.
Woo, E. Y., et al. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research, 61(12), 4766–4772.PubMed
57.
Curiel, T. J., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Natural Medicines, 10(9), 942–949.
58.
Bluestone, J. A., & Abbas, A. K. (2003). Natural versus adaptive regulatory T cells. Nature Reviews. Immunology, 3(3), 253–257.PubMed
59.
Sakaguchi, S. (2004). Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annual Review of Immunology, 22, 531–562.PubMed
60.
Read, S., & Powrie, F. (2001). CD4(+) regulatory T cells. Current Opinion in Immunology, 13(6), 644–649.PubMed
61.
Wolf, D., et al. (2005). The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clinical Cancer Research, 11(23), 8326–8331.PubMed
62.
Leffers, N., et al. (2009). Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy, 58(3), 449–459.PubMed
63.
Wherry, E. J., & Ahmed, R. (2004). Memory CD8 T-cell differentiation during viral infection. Journal of Virology, 78(11), 5535–5545.PubMed
64.
Sharpe, A. H., & Freeman, G. J. (2002). The B7-CD28 superfamily. Nature Reviews. Immunology, 2(2), 116–126.PubMed
65.
Chen, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature Reviews. Immunology, 4(5), 336–347.PubMed
66.
Okazaki, T., & Honjo, T. (2006). The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology, 27(4), 195–201.PubMed
67.
Barber, D. L., et al. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439(7077), 682–687.PubMed
68.
Day, C. L., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443(7109), 350–354.PubMed
69.
Trautmann, L., et al. (2006). Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Natural Medicines, 12(10), 1198–1202.
70.
Freeman, G. J., et al. (2006). Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. The Journal of Experimental Medicine, 203(10), 2223–2227.PubMed
71.
Kim, P. S., & Ahmed, R. (2010). Features of responding T cells in cancer and chronic infection. Curr Opin Immunol, 22(2), 223–230.PubMed
72.
73.
Chemnitz, J. M., et al. (2004). SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology, 173(2), 945–954.
74.
Nishimura, H., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291(5502), 319–322.PubMed
75.
Dong, H., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Natural Medicines, 8(8), 793–800.
76.
Inman, B. A., et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer, 109(8), 1499–1505.PubMed
77.
Nomi, T., et al. (2007). Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical Cancer Research, 13(7), 2151–2157.PubMed
78.
Thompson, R. H., Dong, H., & Kwon, E. D. (2007). Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clinical Cancer Research, 13(2 Pt 2), 709s–715s.PubMed
79.
Ahmadzadeh, M., et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544.PubMed
80.
Matsuzaki, J., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A, 107(17), 7875–7880.
81.
Ercolini, A. M., et al. (2005). Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. The Journal of Experimental Medicine, 201(10), 1591–1602.PubMed
82.
Thompson, R. H., et al. (2007). PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical Cancer Research, 13(6), 1757–1761.PubMed
83.
Quezada, S. A., et al. (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation, 116(7), 1935–1945.PubMed
84.
Li, B., et al. (2009). Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clinical Cancer Research, 15(5), 1623–1634.PubMed
85.
Curran, M.A. and J.P. Allison, Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. Cancer Res, 2009.
86.
Li, Q., et al. (2007). Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. International Journal of Biological Sciences, 3(7), 455–462.PubMed
87.
Brahmer, J.R., et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 28(19): p. 3167-75.
88.
Butte, M. J., et al. (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 27(1), 111–122.PubMed
89.
Ohigashi, Y., et al. (2005). Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clinical Cancer Research, 11(8), 2947–2953.PubMed
90.
Francisco, L.M., P.T. Sage, and A.H. Sharpe, The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 236: p. 219-42.
91.
Frumento, G., et al. (2002). Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. The Journal of Experimental Medicine, 196(4), 459–468.PubMed
92.
Terness, P., et al. (2002). Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. The Journal of Experimental Medicine, 196(4), 447–457.PubMed
93.
Della Chiesa, M., et al. (2006). The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood, 108(13), 4118–4125.
94.
Munn, D. H., & Mellor, A. L. (2007). Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. The Journal of Clinical Investigation, 117(5), 1147–1154.PubMed
95.
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008). Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunological Reviews, 222, 206–221.PubMed
96.
Sharma, M. D., et al. (2007). Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. The Journal of Clinical Investigation, 117(9), 2570–2582.PubMed
97.
Chen, W., Liang, X., Peterson, A. J., et al. (2008). The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. Journal of Immunology, 181(8), 5396–5404.
98.
Brandacher, G., et al. (2006). Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clinical Cancer Research, 12(4), 1144–1151.PubMed
99.
Pan, K., et al. (2008). Expression and prognosis role of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 134(11), 1247–1253.PubMed
100.
Ino, K., et al. (2006). Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. British Journal of Cancer, 95(11), 1555–1561.PubMed
101.
Ino, K., et al. (2008). Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clinical Cancer Research, 14(8), 2310–2317.PubMed
102.
Inaba, T., et al. (2010). Indoleamine 2, 3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecologic Oncology, 117(3), 423–428.PubMed
103.
Okamoto, A., et al. (2005). Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clinical Cancer Research, 11(16), 6030–6039.PubMed
104.
Takao, M. (2007). O.A., Nikaido T, et al, Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of ovarian cancer. Oncology Reports, 17, 1333–1339.PubMed
105.
Inaba, T., et al. (2009). Role of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase in the progression of ovarian carcinoma. Gynecologic Oncology, 115(2), 185–192.PubMed
106.
Qian, F., et al. (2009). Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2, 3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Research, 69(13), 5498–5504.PubMed
107.
Yoshida, N., et al. (2008). Overexpression of indoleamine 2, 3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clinical Cancer Research, 14(22), 7251–7259.PubMed
108.
Dudley, M. E., et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298(5594), 850–854.PubMed
109.
Peggs, K. S., et al. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine, 206(8), 1717–1725.PubMed
110.
Shrimali, R. K., et al. (2010). Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer. Cancer Research, 70(15), 6171–6180.PubMed
111.
Buckanovich, R. J., et al. (2008). Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Natural Medicines, 14(1), 28–36.
112.
Mazanet, M. M., & Hughes, C. C. W. (2002). B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. Journal of Immunology, 169(7), 3581–3588.
113.
Rodig, N., et al. (2003). Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. European Journal of Immunology, 33(11), 3117–3126.PubMed
114.
Sata, M., & Walsh, K. (1998). Oxidized LDL activates fas-mediated endothelial cell apoptosis. The Journal of Clinical Investigation, 102(9), 1682–1689.PubMed
115.
Secchiero, P., et al. (2006). Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation, 114(14), 1522–1530.PubMed
116.
Hernandez-Alcoceba, R., et al. (2001). Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Therapy, 8(4), 298–307.PubMed
117.
Pirtskhalaishvili, G. (2000). Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. Journal of Immunology, 165, 1956–1964.
118.
Batista, F. D., & Harwood, N. (2009). The who, how and where of antigen presentation to B cells. Nature Reviews. Immunology, 9(1), 15–27.PubMed
119.
Grant, K., Loizidou, M., & Taylor, I. (2003). Endothelin-1: a multifunctional molecule in cancer. British Journal of Cancer, 88(2), 163–166.PubMed
120.
Kedzierski, R. M., & Yanagisawa, M. (2001). Endothelin system: the double-edged sword in health and disease. Annual Review of Pharmacology and Toxicology, 41, 851–876.PubMed
121.
Yanagisawa, H., et al. (1998). Role of Endothelin-1/Endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice. The Journal of Clinical Investigation, 102(1), 22–33.PubMed
122.
Meidan, R., & Levy, N. (2007). The ovarian endothelin network: an evolving story. Trends in Endocrinology and Metabolism, 18(10), 379–385.PubMed
123.
Nelson, J., et al. (2003). The endothelin axis: emerging role in cancer. Nature Reviews. Cancer, 3(2), 110–116.PubMed
124.
Bagnato, A., & Rosano, L. (2008). The endothelin axis in cancer. The International Journal of Biochemistry & Cell Biology, 40(8), 1443–1451.
125.
Yanagisawa, M., & Masaki, T. (1989). Molecular biology and biochemistry of the endothelins. Trends in Pharmacological Sciences, 10(9), 374–378.PubMed
126.
Saida, K., Mitsui, Y., & Ishida, N. (1989). A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. The Journal of Biological Chemistry, 264(25), 14613–14616.PubMed
127.
Valdenaire, O., Rohrbacher, E., & Mattei, M. G. (1995). Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). The Journal of Biological Chemistry, 270(50), 29794–29798.PubMed
128.
Frommer, K. W., & Muller-Ladner, U. (2008). Expression and function of ETA and ETB receptors in SSc. Rheumatology (Oxford), 47(Suppl 5), v27–v28.
129.
Luscher, T. F., & Barton, M. (2000). Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 102(19), 2434–2440.PubMed
130.
Salani, D., et al. (2000). Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. The American Journal of Pathology, 157(5), 1703–1711.PubMed
131.
Jesmin, S., et al. (2006). Down-regulated VEGF expression in the diabetic heart is normalized by an endothelin ETA receptor antagonist. European Journal of Pharmacology, 542(1–3), 184–185.PubMed
132.
Kato, T., et al. (2001). Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer. Breast Cancer Research and Treatment, 70(1), 65–74.PubMed
133.
Spinella, F., et al. (2004). Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. Journal of Cardiovascular Pharmacology, 44, S140–S143.PubMed
134.
Spinella, F., et al. (2007). Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Research, 67(4), 1725–1734.PubMed
135.
Rosano, L., et al. (2003). Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. The American Journal of Pathology, 163(2), 753–762.PubMed
136.
Rosano, L., et al. (2003). Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Research, 63(10), 2447–2453.PubMed
137.
Spinella, F., et al. (2002). Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. The Journal of Biological Chemistry, 277(31), 27850–27855.PubMed
138.
Spinella, F., et al. (2004). Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clinical Cancer Research, 10(14), 4670–4679.PubMed
139.
Arnett, B., et al. (2003). Expression of CAAT enhancer binding protein beta (C/EBP beta) in cervix and endometrium. Molecular Cancer, 2, 21.PubMed
140.
Merogi, A. J., et al. (1997). Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Human Pathology, 28(3), 321–331.PubMed
141.
Wanecek, M., et al. (2000). The endothelin system in septic and endotoxin shock. European Journal of Pharmacology, 407(1–2), 1–15.PubMed
142.
Sampaio, A. L., Rae, G. A., & Henriques, M. G. (2004). Effects of endothelin ETA receptor antagonism on granulocyte and lymphocyte accumulation in LPS-induced inflammation. Journal of Leukocyte Biology, 76(1), 210–216.PubMed
143.
Sampaio, A. L., Rae, G. A., & Henriques, M. M. (2000). Role of endothelins on lymphocyte accumulation in allergic pleurisy. Journal of Leukocyte Biology, 67(2), 189–195.PubMed
144.
Rajeshkumar, N. V., Rai, A., & Gulati, A. (2005). Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Research and Treatment, 94(3), 237–247.PubMed
145.
Wulfing, P., et al. (2003). Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clinical Cancer Research, 9(11), 4125–4131.PubMed
146.
Grimshaw, M. J., et al. (2004). A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Research, 64(7), 2461–2468.PubMed
147.
Balint, K., et al. (2008). Role of vascular leukocytes in ovarian cancer neovascularization. Advances in Experimental Medicine and Biology, 622, 273–280.PubMed
148.
Halcox, J. P., et al. (2007). Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension, 49(5), 1134–1141.PubMed
149.
Cardillo, C., et al. (1999). Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension, 33(2), 753–758.PubMed
150.
Cowburn, P. J., et al. (2005). Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. European Journal of Heart Failure, 7(1), 37–42.PubMed
151.
Hodi, F. S., & Dranoff, G. (2006). Combinatorial cancer immunotherapy. Advances in Immunology, 90, 341–368.PubMed
152.
Cemazar, M., et al. (2005). The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. British Journal of Cancer, 93(1), 98–106.PubMed
Metadata
Title
Tumor immune surveillance and ovarian cancer
Lessons on immune mediated tumor rejection or tolerance
Authors
Lana E. Kandalaft
Gregory T. Motz
Jaikumar Duraiswamy
George Coukos
Publication date
01-03-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9289-9

Other articles of this Issue 1/2011

Cancer and Metastasis Reviews 1/2011 Go to the issue

OriginalPaper

How to improve the immunogenicity of chemotherapy and radiotherapy

OriginalPaper

Immunomodulating antibodies and drugs for the treatment of hematological malignancies

OriginalPaper

Modulation of tumor immunity by therapeutic monoclonal antibodies

OriginalPaper

Tumor microenvironment is multifaceted

OriginalPaper

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

OriginalPaper

Improving cancer immunotherapy by targeting tumor-induced immune suppression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits